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We report the first case of multifocal Scedosporium apiospermum spondylitis in a cystic fibrosis patient. The infection, which occurred
during voriconazole prophylaxis, disseminated contiguously from the base of the left lung and pleura and spread to vertebrae via the epidural
space. S. apiospermum osteoarticular infections are rare, and are difficult to diagnose and cure because of their resistance to anti-fungal drugs.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Scedosporium apiospermum; Spondylitis; Cystic fibrosis1. Introduction
Scedosporium apiospermum, the asexual anamorph of
Pseudallescheria boydii, is a ubiquitous saprophytic fila-
mentous fungus found in soil, decaying vegetation, and
polluted water. It may cause cutaneous, subcutaneous and
pulmonary infections in immunocompetent patients. It may
also be responsible for life-threatening central nervous
system, ocular [1] or endovascular [2] disease, especially
in immunocompromised patients, and is associated with a
high mortality rate in such cases (75%) [3]. It is rarely found
in osteoarticular and spinal locations, but osteomyelitis,
peripheral arthritis, spondylitis, paravertebral abscess and
discitis have been described [4,5]. Such conditions occur
after a local trauma in immunocompetent hosts. Dissemina-
tion may be contiguous or haematogenous, particularly in
immunocompromised patients [6]. Diagnosis is difficult and
often delayed due to negative cultures [7]. S. apiospermum is⁎ Corresponding author. Tel.: +33 1 58 41 23 78; fax: +33 1 58 41 23 62.
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doi:10.1016/j.jcf.2007.05.003resistant to traditional anti-fungal drugs, such as amphoter-
icin B, making it difficult to treat infections. Treatment with
newer triazole compounds (posaconazole, voriconazole)
[8,9], seems to be more effective. Surgical debridement or
spinal reconstruction may be required. We report here the
first case of multifocal S. apiospermum spondylitis in a
patient with cystic fibrosis (CF) who previously presented
respiratory tract colonisation with this fungus.
2. Case report
This 28-year-old man was diagnosed with CF at the age of
three years following recurrent episodes of bronchitis. He
had pancreatic insufficiency and diabetes was diagnosed in
2003. The respiratory tract was colonised with Staphylo-
coccus aureus at the time of diagnosis and was known to be
colonised with S. apiospermum since 1993. In October
2002, left pleurisy was diagnosed, the cause of which was
not identified. The patient was treated with voriconazole per
os because S. apiospermum was identified in sputum. At this
time, the patient's forced vital capacity (FVC) was 84% theed by Elsevier B.V. All rights reserved.
Fig. 2. Magnetic resonance imaging (T1 gadolinum): T2–T6 Scedosporium
apiospermum spondylitis with epiduritis and spinal abscess.
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1 s (FEV1) was 60% pred. His body mass index (BMI) was
19.6 kg/m2. Chest computed tomography scans showed
diffuse bronchiectasis predominating in the left lower lobe,
with segmental atelectasis and mild left pleural effusion.
Pleural puncture was not possible due to the small amount of
pleural fluid. In December 2004, the patient (who was still on
voriconazole treatment) began to complain of inflammatory
back pain without fever and weight loss (3 kg). FVC was 56%
pred. and FEV1 36% pred., BMI was 18.2 kg/m2. In April
2005, X rays of the back showed D12 costo-vertebral arthritis.
Dorsal magnetic resonance imaging (MRI) revealed spondy-
litis of D2 to D5, D11 and D12 with no discitis but with costo-
vertebral arthritis, epiduritis and abscesses (Figs. 1 and 2). The
pleuro-pulmonary lesions of the lower left lung communicated
with the spinal lesions. Sedimentation rate for the first hour
was 120 mm and C-reactive protein concentration (CRP) was
172 mg/L. All classical tests for infection were negative,
except for the persistence of S. apiospermum and S. aureus in
sputum. Primary colonisation with Pseudomonas aeruginosa
was discovered at this time and a first intravenous (IV)
antibiotic course (ceftazidime, ciprofloxacin and amikacin)
was administered. A tuberculin test was negative, as were
repeated cultures of sputum for mycobacteria and Widal Felix
serological tests. Three radiological vertebral biopsies were
carried out after two weeks of antibiotic treatment and
voriconazole wash-out. All bacteriological, mycological and
histological analyses on the biopsy samples were negative.
Empirical IV oxacillin and gentamycin treatment against S.
aureus was initiated. One month later, the patient was still in
considerable pain and required morphine, blood test results for
inflammation were unchanged, and MRI showed a progres-
sion of the lesions, with the appearance of D6, D7, D8 and D9Fig. 1. Magnetic resonance imaging (T2): Multifocal dorsal Scedosporium
apiospermum spondylitis with paravertebral abscesses and contiguous
pleurisy.spondylitis. The antibiotic treatment was stopped and a
surgical biopsy was carried out 15 days later. This biopsy
revealed the presence of S. apiospermum. IV caspofungine
(70 mg/d) treatment and per os posaconazole (800 mg/d)
treatment were administered for six months without success.
The minimum inhibitory concentrations (MIC) obtained for
the S. apiospermum isolated from sputum were 32 μg/ml
for amphotericin B, N32 μg/ml for itraconazole, 0.38 μg/ml
for voriconazole, 1.5 μg/ml for posaconazole and 0.25 μg/ml
for caspofungine. In January 2006, posaconazole treatment was
stopped and IV voriconazole (400 mg/d) was introduced, in
combination with the existing caspofungine treatment. In July
2006, oral voriconazole (400 mg/d) was added to the treatment
regime. Pain and the inflammatory syndrome progressively
decreased. In March 2007, CRP concentration had fallen to
14 mg/L, and the radiological lesions had stabilised. S.
apiospermum persisted in the sputum, together with S. aureus,
and P. aeruginosa was detected intermittently. FVC was 62%
pred. and FEV1, 37% pred., BMI was 18.8 kg/m2. Caspo-
fungine treatment was stopped at the end of March 2007. We
plan to stop IV voriconazole treatment at the end of April 2007
but to continue oral voriconazole treatment at a higher dose
(400 mg three times daily). Serum voriconazole concentrations
were determined several times between January 2006 and
March 2007, and ranged between 0.41 and 0.84mg/L after 12 h
of treatment with 400 mg IV voriconazole and between 1.56
and 3.30 mg/L after 4 h of 400 mg voriconazole per os.
3. Discussion
S. apiospermum airway colonisation is not rare in CF
patients, but its pathogenicity remains a matter of debate
[10]. Malnutrition and diabetes may constitute risk factors
for severe S. apiospermum infection, accounting for the
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the impressive extension of spine lesions. As in this case,
several other case reports have highlighted the difficulty
involved in diagnosis, with a long time interval between
onset and diagnosis. Several successive biopsies may be
required. Published studies suggest that radiological biopsies
are as effective as surgical biopsies for the detection of
infectious agents. In this case, no diagnosis could be made
after several radiological biopsies and only the surgical
biopsy was successful. We first suspected S. aureus
infection, given its frequency, the type of lesions (abscess,
epiduritis, costo-vertebral arthritis) and the chronic bronchial
infection with S. aureus. Nevertheless, the progressive
evolution, the absence of discitis and the lack of response
to classical antibiotics ruled out this diagnosis. P. aerugi-
nosa, which was present in sputum, could also have been
responsible for spondylitis, but was not isolated from
vertebral biopsy samples. The most frequent osteoarticular
infection known to cause spondylitis without discitis is
tuberculosis, but neither repeated bacteriological tests nor
histological analyses supported this diagnosis. Costo-
vertebral arthritis is more frequent in fungal infections, as
in this patient. The infection may have disseminated
contiguously from the pleural fluid to the vertebrae, via the
epidural space. S. apiospermum is known to be particularly
resistant to anti-fungal drugs (particularly amphotericin B, the
classical treatment for fungal infections), making it very
difficult to cure. The infection occurred as a breakthrough
infection during treatment with voriconazole, which is
recommended for the treatment of Scedosporium infections.
No plasma or sputum concentrations of voriconazole were
determined for this patient before the diagnosis of spondylitis,
but the anti-fungal treatment was considered to have failed.
Poor intestinal absorption of voriconazole may have been
responsible for its lack of efficacy, as residual voriconazole
serum concentrations measured after the reinitiation of vori-conazole treatment were low. Nevertheless, increasing the
dose and supplying this drug via the IV route, then by the oral
and IV route, and association with another anti-fungal drug
improved efficacy.
4. Conclusion
S. apiospermum rarely infects osteoarticular sites in
immunocompetent patients. This is the first reported case in
a CF patient. This fungal infection can be difficult to diag-
nose and cure.
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